Immune Responses Induced by Recombinant Bacillus subtilis Expressing the PEDV Spike Protein Targeted at Microfold Cells

Lin, Jian; Mou, Chunxiao; Zhang, Shuai; Zhu, Liqi; Li, Yuchen; Yang, Qian

doi:10.3390/vetsci9050211

Cited by 3 publications

(3 citation statements)

References 37 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the full-length S, S1, and COE of PEDV are the primary targets for vaccine development. In recent years, different forms of S, S1, and COE, expressed in various expression systems (e.g., mammalian cells, Escherichia coli , baculovirus, Bacillus subtilis , adenovirus, and Lactobacillus ), have been used as immunogens to develop PEDV vaccines ( 33 – 37 ). Our previous study found that a subunit vaccine based on the PEDV Sm, composed of the NTD, COE, and several linear neutralizing epitopes, induced an effective immune response against PEDV ( 26 ).…”

Section: Discussionmentioning

confidence: 99%

PEDV-spike-protein-expressing mRNA vaccine protects piglets against PEDV challenge

Zhao,

Fan,

Song

et al. 2024

mBio

View full text Add to dashboard Cite

Porcine epidemic diarrhea virus (PEDV), a swine enteropathogenic coronavirus, causes severe diarrhea in neonatal piglets, which is associated with a high mortality rate. Thus, developing effective and safe vaccines remains a top priority for controlling PEDV infection. Here, we designed two lipid nanoparticle (LNP)-encapsulated mRNA (mRNA-LNP) vaccines encoding either the full-length PEDV spike (S) protein or a multiepitope chimeric spike (Sm) protein. We found that the S mRNA-LNP vaccine was superior to the Sm mRNA-LNP vaccine at inducing antibody and cellular immune responses in mice. Evaluation of the immunogenicity and efficacy of the S mRNA vaccine in piglets confirmed that it induced robust PEDV-specific humoral and cellular immune responses in vivo . Importantly, the S mRNA-LNP vaccine not only protected actively immunized piglets against PEDV but also equipped neonatal piglets with effective passive anti-PEDV immunity in the form of colostrum-derived antibodies after the immunization of sows. Our findings suggest that the PEDV-S mRNA-LNP vaccine is a promising candidate for combating PEDV infection. IMPORTANCE Porcine epidemic diarrhea virus (PEDV) continues to harm the global swine industry. It is important to develop a highly effective vaccine to control PEDV infection. Here, we report a PEDV spike (S) mRNA vaccine that primes a potent antibody response and antigen-specific T-cell responses in immunized piglets. Active and passive immunization can protect piglets against PED following the virus challenge. This study highlights the efficiency of the PEDV-S mRNA vaccine and represents a viable approach for developing an efficient PEDV vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

PEDV-spike-protein-expressing mRNA vaccine protects piglets against PEDV challenge

Zhao,

Fan,

Song

et al. 2024

mBio

View full text Add to dashboard Cite

show abstract

“…Modern treatment has many side effects from the drugs used. Consequently, there is a need to create a vaccine against this disease [141,142]. Based on Lpb.…”

Section: Development Of Vaccines Against Trichinellosismentioning

confidence: 99%

“…In addition, an increased number of cytokines, interleukins and CD4+ type cells were indicated. After infecting immunized mice with pathogenic larvae, there was a 75.67% decrease in the number of adult worms 7 days after infection along with encysted larvae on the tongue and masticatory muscles [142]. Another study also used Lpb.…”

Section: Development Of Vaccines Against Trichinellosismentioning

confidence: 99%

Recombinant Probiotic Preparations: Current State, Development and Application Prospects

Khablenko

Danylenko

Yalovenko

et al. 2023

Innov Biosyst Bioeng

View full text Add to dashboard Cite

The article is devoted to the latest achievements in the field of research, development, and implementation of various types of medicinal products based on recombinant probiotics. The benefits of probiotics, their modern use in medicine along with the most frequently used genera and species of probiotic microorganisms were highlighted. The medicinal and therapeutic activities of the studied probiotics were indicated. The review suggests various methods of creating recombinant probiotic microorganisms, including standard genetic engineering methods, as well as systems biology approaches and new methods of using the CRISPR-Cas system. The range of potential therapeutic applications of drugs based on recombinant probiotics was proposed. Special attention was paid to modern research on the creation of new, more effective recombinant probiotics that can be used for various therapeutic purposes. Considering the vast diversity of therapeutic applications of recombinant probiotics and ambiguous functions, their use for the potential treatment of various common human diseases (non-infectious and infectious diseases of the gastrointestinal tract, metabolic disorders, and allergic conditions) was investigated. The prospects for creating different types of vaccines based on recombinant probiotics together with the prospects for their implementation into medicine were considered. The possibilities of using recombinant probiotics in veterinary medicine, particularly for the prevention of domestic animal diseases, were reviewed. The prospects for the implementation of recombinant probiotics as vaccines and diagnostic tools for testing certain diseases as well as modeling the work of the human digestive system were highlighted. The risks of creation, application, including the issues related to the regulatory sphere regarding the use of new recombinant microorganisms, which can potentially enter the environment and cause unforeseen circumstances, were outlined.

show abstract

Effect of the probiotic feed additive “Immunobacterin-D” on the productivity of black speckled cows during lactation

Pogranichniy,

Lytvynenko,

Vergeles

2023

Ukrainian journal of veterinary sciences

View full text Add to dashboard Cite

In Ukraine, as in every country in the world, an important task is to develop an effective development strategy for producing natural dairy products through probiotics. Feeding PFA to animals shows different effectiveness depending on their age, the intestinal microbiome's characteristics, the feed diet's composition and production technology. The purpose of the study was to identify the most effective period of application of PFA “Immunobacterin-D" and to select a yeast culture to increase the milk productivity of cows. The effectiveness of PFA was evaluated by the amount of milk produced, and its quality – by using an Ecomilk ultrasound analyser. The health status of cows was monitored based on the results of a spectrophotometric study of biochemical parameters of blood serum on a LabLine-010 biochemical analyser (Austria). As a result, it was determined that the optimal period of application of PFA is 30-60 days after calving. On the 13th day of PFA feeding, milk yields in cows of the experimental group increased by 1.2-2.5 L/day. The difference in the amount of milk produced between the animals of the experimental and control groups was 0.7-1.9 L/day. From 70 days after calving, the use of PFA in cows did not cause changes in the volume of milk yield but contributed to an increase in its fat content. By feeding cows of the experimental strain for 21 days S. cerevisiae as part of the PFA, the maximum increase in milk yield was obtained – by 2.13 L, and milk fat – by 0.45%. Whereas the use of PFA with a conventional strain S. cerevisiae AF 338 contributed to an increase in milk yield by 1.73 L, and in the control group of cows only by 1.30 L. According to the results of biochemical studies of blood serum, the positive effect of PFA “Immunobacterin-D” on the health status of cows was proved. PFA can be recommended for feeding cows in production, which will help increase milk yield and improve their health

show abstract

Immune Responses Induced by Recombinant Bacillus subtilis Expressing the PEDV Spike Protein Targeted at Microfold Cells

Cited by 3 publications

References 37 publications

PEDV-spike-protein-expressing mRNA vaccine protects piglets against PEDV challenge

PEDV-spike-protein-expressing mRNA vaccine protects piglets against PEDV challenge

Recombinant Probiotic Preparations: Current State, Development and Application Prospects

Effect of the probiotic feed additive “Immunobacterin-D” on the productivity of black speckled cows during lactation

Contact Info

Product

Resources

About